about
Tissue and soluble biomarkers in breast cancer and their applications: ready to use?High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer.Molecular and functional characterization of a new 3' end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant ImatinibThe Prognosis of Patients with Liver Metastases from Colorectal Cancer still Depends on Anatomical Presentation more than on Treatments.A six-colour flow cytometric method for simultaneous detection of cell phenotype and apoptosis of circulating endothelial cells.In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status.Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN).Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter AnalysisSimultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapyChemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimensPreoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm studyPhase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trialComparison of pathology sampling protocols for pancreatoduodenectomy specimensThe Italian Rare Pancreatic Exocrine Cancer Initiative
P50
Q39691585-A6135D20-A5AE-438C-B3F5-082C12B138B8Q40847140-6A1B0705-3FD2-456A-9032-BA8B95FD36F1Q41347601-8FD53C47-2837-4BF0-AA7D-B9DE0F637677Q41475396-768872B2-6E40-4A32-92CF-7501FB73C46CQ46165524-F76F25A4-DE9B-48CB-A290-D1F4575D75E6Q47224624-21AF2F90-A73D-45C8-B198-E780A1F895A9Q48018929-BA0A7DF2-CD22-4A13-8F6D-43754E5C5822Q55019941-0516FDAA-A1E3-4860-A902-0B1179D2A0F7Q57178818-C3734676-61B0-4BE7-89F3-FED3F3379B53Q60169775-8B002ABE-9CC9-4EE6-AE9A-E4E86FCEC106Q60169778-D7B34258-D829-4A44-ACCE-D524F02BE719Q90106949-9AAEDEF2-98A8-4242-8FA6-EABB5548323DQ91422596-EE73480A-031C-4B3C-B02A-E8F8653EC18BQ91699862-FB40D3DF-D380-480E-AE3A-A19D16809957Q92983264-85EA218C-6ABA-4915-BA53-9BDC78BE43BF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sara Delfanti
@en
Sara Delfanti
@nl
type
label
Sara Delfanti
@en
Sara Delfanti
@nl
prefLabel
Sara Delfanti
@en
Sara Delfanti
@nl
P31
P496
0000-0002-9862-7340